JP2021534757A5 - - Google Patents

Info

Publication number
JP2021534757A5
JP2021534757A5 JP2021509865A JP2021509865A JP2021534757A5 JP 2021534757 A5 JP2021534757 A5 JP 2021534757A5 JP 2021509865 A JP2021509865 A JP 2021509865A JP 2021509865 A JP2021509865 A JP 2021509865A JP 2021534757 A5 JP2021534757 A5 JP 2021534757A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
amino acid
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534757A (ja
JP7713880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047330 external-priority patent/WO2020041361A1/en
Publication of JP2021534757A publication Critical patent/JP2021534757A/ja
Publication of JP2021534757A5 publication Critical patent/JP2021534757A5/ja
Priority to JP2025044879A priority Critical patent/JP2025118591A/ja
Application granted granted Critical
Publication of JP7713880B2 publication Critical patent/JP7713880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509865A 2018-08-20 2019-08-20 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド Active JP7713880B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044879A JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765284P 2018-08-20 2018-08-20
US62/765,284 2018-08-20
PCT/US2019/047330 WO2020041361A1 (en) 2018-08-20 2019-08-20 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044879A Division JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Publications (3)

Publication Number Publication Date
JP2021534757A JP2021534757A (ja) 2021-12-16
JP2021534757A5 true JP2021534757A5 (https=) 2022-10-25
JP7713880B2 JP7713880B2 (ja) 2025-07-28

Family

ID=69591189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021509865A Active JP7713880B2 (ja) 2018-08-20 2019-08-20 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド
JP2025044879A Pending JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044879A Pending JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Country Status (7)

Country Link
US (2) US20210340268A1 (https=)
EP (1) EP3840782A4 (https=)
JP (2) JP7713880B2 (https=)
KR (2) KR20210061350A (https=)
CN (1) CN112955179A (https=)
CA (1) CA3109954A1 (https=)
WO (1) WO2020041361A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936137A1 (en) * 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
EP4149627A4 (en) * 2020-05-14 2024-05-29 The General Hospital Corporation POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合ｔｎｆｒ２的抗體及其用途
CN112159818B (zh) * 2020-08-20 2023-02-21 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
US20240101693A1 (en) * 2021-01-21 2024-03-28 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN117858893A (zh) * 2021-06-30 2024-04-09 盛禾(中国)生物制药有限公司 一种抗tnfr2单域抗体及其制备方法和应用
CN116334768A (zh) * 2022-07-14 2023-06-27 上海肽盛医药有限公司 一种结构多样的多肽库及其构建方法和应用
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CN1771055A (zh) * 2002-09-05 2006-05-10 免疫医疗公司 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
AU2015237864B2 (en) * 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US11859002B2 (en) * 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
BR112019001206A2 (pt) * 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
WO2018031400A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG10201912565QA (en) * 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
WO2018092907A1 (ja) * 2016-11-21 2018-05-24 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽

Similar Documents

Publication Publication Date Title
JP2021534757A5 (https=)
JP2025118591A5 (https=)
FI3447075T3 (fi) Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
JP6187257B2 (ja) 癌の治療及び／又は予防用医薬組成物
JP2010532169A5 (https=)
JP2013502913A5 (https=)
JP2020517591A (ja) 抗ｃｄ３３抗体剤
JP2022520998A5 (https=)
JP2019523630A5 (https=)
JP2021510736A5 (https=)
JP2014527814A5 (https=)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
US20250074980A1 (en) Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
JP2021520201A5 (https=)
JP6933724B2 (ja) Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物
JP2024515560A5 (https=)
US20250388682A1 (en) Degradation of egfr using a bispecific binding agent
KR20250169224A (ko) 암의 치료를 위한 항체, 또는 그의 항원-결합 단편의 조합물 및 그의 조성물
JP2023525991A5 (https=)
CN113038939A (zh) 损害内施用pd-1抑制剂用于治疗皮肤癌
JP2022539628A (ja) Ｈｐｖ ｅ６特異性およびｐｄ－１遮断性を有する二重機能性改変ｔ細胞
CN109414492A (zh) 针对cd81的人源化和嵌合单克隆抗体
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体
WO2026037330A1 (en) Antibodies binding to cd3 and uses thereof
KR20250004624A (ko) T 세포 및 nk 세포 인게이저